Amyloid alone does not confirm that Alzheimer's disease is progressing rapidly. Here's what people need to know about the ...

Researchers from the International Working Group recommend categorizing biomarker-positive, cognitively normal individuals as ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Every anti-amyloid antibody is different, hence the donanemab AUR address two unique aspects of this drug: in its Phase 3 trial, scientists used baseline tau PET scans to determine eligibility, and ...

The memorandum of understanding (MOU) between the companies aims to advance the development of imaging agents used in PET ...

Weill Cornell Medicine researchers have received a five-year $6.2 million grant from the National Institute on Aging, part of the National Institutes of Health, to build a portable, high-resolution ...

Pharmaceuticals presented updated data on a validated research-use plasma pTau217 assay to screen potential participants in the ...

Lucent Diagnostics, a brand of Quanterix Corporation, has introduced LucentAD Complete, a new multi-marker blood test designed to help detect Alzheimer’s Disease (AD) in a broad ...

Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), has introduced LucentAD Complete, a new multi-marker blood test designed to help detect Alzheimer’s Disease (AD) in a broader range ...

New data highlight the potential of the Roche Elecsys® Amyloid Plasma Panel and Elecsys ptau181 for ruling out Alzheimer’s disease related amyloid pathology with very good accuracy. In the largest ...

Welcome to the Lantheus Third Quarter 2024 Conference Call. All lines have been placed on mute. This call is being recorded and a replay will be available in the Investors section of the company's ...

Eli Lilly Saudi Arabia and King Faisal Specialist Hospital & Research Centre (KFSHRC) have teamed up to make KFSHRC’s Neuroscience Centre a top regional hub for Alzheimer’s disease treatment.